Related Research


  • Pathmanandavel S, Crumbaker M, Yam AO, Nguyen A, Rofe C, Hovey E, Gedye C, Kwan EM, Hauser C, Azad AA, Eu P, Martin AJ, Joshua AM, Emmett L. 177Lutetium PSMA-617 and idronoxil (NOX66) in men with end-stage metastatic castrate-resistant prostate cancer (LuPIN): Patient outcomes and predictors of treatment response of a Phase I/II trial. J Nucl Med. 2021 Jul 29:jnumed.121.262552.
  • Kiknavelidze K, Shavdia M, Chikhladze N, Abshilava L, Messina M, Mautner G, Kelly G. NOX66 as Monotherapy, and in Combination With Carboplatin, in Patients With Refractory Solid Tumors: Phase Ia/b Study. Curr Ther Res Clin Exp. 2021 Mar 8;94:.DOI: 10.1016/j.curtheres.2021.100631
  • Crumbaker M, Pathmanandavel S, Yam A, Nguyen A, Ho B, Chan L, Ende J, Rofe C, Kongrak K, Kwan E, Azad A, Sharma S, Pugh T, Danesh A, Keane J, Eu P, Joshua A, Emmett L (2020). Phase I/II Trial of the Combination of 177Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN). European Urology Oncology.
  • de Souza PL, Capp AL, Chikhladze N, Mezvrishvili Z, Messina M, Mautner G. Phase I study of a novel S1P inhibitor, NOX66, in combination with radiotherapy in patients with metastatic castration-resistant prostate cancer. Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 5533-5533. DOI: 10.1200/JCO.2020.38.15_suppl.5533
  • de Souza PL, Messina M, Minns I, Shavdia M, Chikhladze N, Kelly G. A phase 1 study of NOX66 in combination with carboplatin in patients with end stage solid tumours. DOI: 10.1200/JCO.2018.36.15_suppl.2585 


  • Morré, DJ, Morré, DM. Cell surface NADH oxidases (ECTO-NOX proteins) with roles in cancer, cellular time-keeping, growth, aging and neurodegenerative diseases Free Radical Research. 37 (8): 795–808
  • Porter, K et al. Idronoxil as an Anticancer Agent: Activity and Mechanisms. Current Cancer Drug Targets, 2020, 20, 1-14.
  • De Luca, T et al. Downstream targets of altered sphingolipid metabolism in response to inhibition of ENOX2 by phenoxodiol. Biofactors, 2008, 34(3), 253-260. PMID: 19734127 10.3233/BIO-2009-1079
  • De Luca, T et al. NAD+/NADH and/or CoQ/CoQH2 ratios from plasma membrane electron transport may determine ceramide and sphingosine-1-phosphate levels accompanying G1 arrest and apoptosis. Biofactors, 2005, 25(1-4), 43-60.
  • Reimann M-C, et al. Sphingosine-1-phosphate (S1P) in cancer immunity and development. Transl Cancer Res. 2015;4(5):460-8.
  • Rodriguez et al. Sphingosine-1 phosphate: A new modulator of immune plasticity in the tumor microenvironment. Frontiers Oncol. 2016; 6:218.
  • Nakajima M, et al. The role of sphingosine-1-phosphate in the tumor microenvironment and its clinical implications. Tumor Biol. 2017;39(4):
  • Pyne NJ, et al. Sphingosine 1-phosphate and cancer. Adv Biol Regulat. 2018;68:97-106.
  • Olesh C. et al. S1PR4 ablation reduces tumor growth and improves chemotherapy via CD8+ T cell expansion.J Clin Invest. 2020;130(10):5461-5476.
  • Tabasinezhad M et al. Sphingosin 1-phosphate contributes in tumor progression. Journal of cancer research and therapeutics. 2013;9(4):556-563.
  • Soo-Jin Parkand Dong-Soon ImSphingosine 1-Phosphate Receptor Modulators and Drug DiscoveryBiomol Ther (Seoul). 2017; 25(1): 80–90.
  • Galon J and Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18(3):197-218
  • Patel SA and Minn AJ. Combination cancer therapy with immune checkpoint blockade: Mechanisms and strategies. Immunity. 2018;48(3):417-33
  • Georgaki, S.; Skopeliti, M.; Tsiatas, M.; Nicolaou, K.A.; Ioannou, K.; Husband, A.; Bamias, A.; Dimopoulos, M.A.; Constantinou, A.I.; Tsitsilonis, O.E. Phenoxodiol, an anticancer isoflavene, induces immunomodulatory effects in vitro and in vivo. J. Cell. Mol. Med., 2009, 13(9B), 3929-3938. PMID: 19220577
  • Yamazaki T et al. (2020) Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy. Nature Immunol 21:1160-1171
  • Miyamoto M et al (2018) Phenoxodiol increases cisplatin sensitivity in ovarian clear cancer cells through XIAP down-regulation and autophagy inhibition. Anticancer Res 38:301-306.  doi: 10.21873/anticanres.12222